New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects

Bookmark and Share
Published: 5 Jun 2017
Views: 1255
Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Dr Shaw presents, at a press conference at ASCO 2017, findings from a phase III clinical trial that point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer.

Read the news story and watch the video interview for more.